Latest Period
Q2 2026
Security Snapshot
Sionna Therapeutics, Inc. - Common Stock, $0.001 par value per share (SION) Institutional Ownership
CUSIP: 829401108
13F Institutional Holders and Ownership History from Q1 2025 to Q2 2026
Institutions Reporting
145
Shares (Excl. Options)
47,961,297
Price
$43.99
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, $0.001 par value per share
- Symbol
- SION on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 47,961,297
- Total 13F value
- $2,108,229,339
- Portfolio coverage rank
- 0%
- Share change
- +2,605,622
- Value change
- +$114,782,540
- Number of holders
- 145
- Shares outstanding
- 45,002,549
- SEC-reported price per share
- $6.54
- Insider filing price
- $6.54
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- SION - Sionna Therapeutics, Inc. - Common Stock, $0.001 par value per share is tracked under CUSIP 829401108.
- 145 institutions reported positions in Q2 2026.
- 8 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 121 to 145 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $1,815,366,651 to $2,108,229,339.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 145 institutions filings for Q2 2026.
Security key
829401108
Latest holder period
Q2 2026
13F holders
145
13D/G owners
8
CIK / CUSIP context first
Open Q2 2026 holders
SION full holder history
Sionna Therapeutics, Inc. SEC filings
Sionna Therapeutics, Inc. company facts
Sionna Therapeutics, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 829401108:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
8
Security
SION
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 23% | -4.6% | $296,218,114 | -$10,988,206 | 10,071,712 | -3.6% | RA Capital Management, L.P. | 05 Nov 2025 |
| TPG GP A, LLC | 15% | $80,486,942 | 6,684,962 | TPG GP A, LLC | 10 Feb 2025 | |||
| VIKING GLOBAL INVESTORS LP | 7.1% | +5.7% | $133,462,710 | +$10,126,176 | 3,195,181 | +8.2% | VIKING GLOBAL INVESTORS LP | 31 Mar 2026 |
| ORBIMED ADVISORS LLC | 6.6% | -22% | $118,970,633 | -$29,554,504 | 2,967,722 | -20% | ORBIMED ADVISORS LLC | 15 Apr 2026 |
| Enavate Sciences GP, LLC | 5.6% | $29,835,481 | 2,478,030 | Enavate Sciences GP, LLC | 10 Feb 2025 | |||
| Atlas Venture Fund XI, L.P. | 5.4% | -16% | $74,744,824 | -$15,805,403 | 2,382,495 | -17% | Atlas Venture Fund XI, L.P. | 16 Oct 2025 |
| Qatar Investment Authority | 4.5% | -10% | $84,386,177 | -$7,916,125 | 2,020,258 | -8.6% | Qatar Investment Authority | 31 Mar 2026 |
| JPMORGAN CHASE & CO | 4.4% | -12% | $58,251,993 | -$7,075,145 | 1,980,626 | -11% | JPMORGAN CHASE & CO. | 30 Sep 2025 |
As of 30 Jun 2026, 145 institutional investors reported holding 47,961,297 shares of Sionna Therapeutics, Inc. - Common Stock, $0.001 par value per share (SION). This represents 107% of the company’s total 45,002,549 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
94%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 22% | 9,905,045 | 0% | 3.8% | $435,722,930 |
| TPG GP A, LLC | 14% | 6,494,962 | 0% | 5.7% | $285,713,378 |
| VIKING GLOBAL INVESTORS LP | 7.1% | 3,195,181 | 0% | 0.4% | $140,556,012 |
| Atlas Venture Life Science Advisors, LLC | 6.7% | 2,995,602 | 0% | 15% | $131,776,532 |
| ORBIMED ADVISORS LLC | 5.7% | 2,555,877 | -28% | 2.1% | $112,433,029 |
| ENAVATE SCIENCES GP, LLC | 5.5% | 2,478,030 | 0% | 32% | $109,008,540 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 3.6% | 1,600,000 | +967% | 0.1% | $70,384,000 |
| JPMORGAN CHASE & CO | 3.3% | 1,490,508 | +1.7% | 0% | $64,085,673 |
| BlackRock, Inc. | 3.3% | 1,474,769 | +14% | 0% | $64,875,089 |
| JENNISON ASSOCIATES LLC | 2.6% | 1,172,133 | -19% | 0.03% | $51,562,131 |
| CITADEL ADVISORS LLC | 2.6% | 1,147,636 | -1.7% | 0.03% | $50,484,507 |
| VANGUARD CAPITAL MANAGEMENT LLC | 2.5% | 1,132,001 | +10% | 0% | $49,796,724 |
| STATE STREET CORP | 2.3% | 1,021,534 | +35% | 0% | $44,937,281 |
| PERCEPTIVE ADVISORS LLC | 2% | 905,000 | +37% | 0.62% | $39,810,950 |
| DEERFIELD MANAGEMENT COMPANY, L.P. | 1.5% | 680,916 | -30% | 0.31% | $29,953,495 |
| Siren, L.L.C. | 1.4% | 610,515 | +104% | 0.55% | $26,856,555 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 1.1% | 478,016 | -37% | 0% | $21,029,000 |
| EVENTIDE ASSET MANAGEMENT, LLC | 1.1% | 474,981 | -26% | 0.28% | $20,894,402 |
| GEODE CAPITAL MANAGEMENT, LLC | 1% | 457,145 | +17% | 0% | $20,113,984 |
| BAKER BROS. ADVISORS LP | 0.89% | 400,000 | 0% | 0.09% | $17,596,000 |
| Casdin Capital, LLC | 0.89% | 400,000 | 0.88% | $17,596,000 | |
| GOLDMAN SACHS GROUP INC | 0.86% | 388,810 | +48% | 0% | $17,103,752 |
| Driehaus Capital Management LLC | 0.86% | 385,447 | +403% | 0.1% | $16,955,814 |
| FRANKLIN RESOURCES INC | 0.64% | 290,113 | +65% | 0% | $12,762,071 |
| Aberdeen Group plc | 0.63% | 284,138 | -50% | 0.02% | $12,499,231 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
6
Latest
Q2 2026
Rows shown
1-6 of 6
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q2 | 47,961,297 | $2,108,229,339 | +$114,782,540 | $43.99 | 145 |
| 2026 Q1 | 45,407,309 | $1,815,366,651 | +$51,789,321 | $40.09 | 121 |
| 2025 Q4 | 43,950,880 | $1,808,143,956 | +$42,254,824 | $41.14 | 101 |
| 2025 Q3 | 42,840,564 | $1,259,943,482 | -$14,718,322 | $29.41 | 78 |
| 2025 Q2 | 43,448,393 | $753,831,077 | +$37,292,994 | $17.35 | 65 |
| 2025 Q1 | 41,491,947 | $434,056,422 | +$434,056,422 | $10.46 | 47 |